These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 15767788)
41. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Lipton A; Zheng M; Seaman J Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563 [TBL] [Abstract][Full Text] [Related]
42. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628 [TBL] [Abstract][Full Text] [Related]
43. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Rosen LS Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692 [TBL] [Abstract][Full Text] [Related]
45. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217 [TBL] [Abstract][Full Text] [Related]
46. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Guest JF; Clegg JP; Davie AM; McCloskey E Curr Med Res Opin; 2005 May; 21(5):805-15. PubMed ID: 15969880 [TBL] [Abstract][Full Text] [Related]
47. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Saad F Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691 [TBL] [Abstract][Full Text] [Related]
48. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. Henk HJ; Kaura S J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235 [TBL] [Abstract][Full Text] [Related]
49. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218 [TBL] [Abstract][Full Text] [Related]
50. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813 [TBL] [Abstract][Full Text] [Related]
51. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Brown JE; Cook RJ; Lipton A; Coleman RE Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824 [TBL] [Abstract][Full Text] [Related]
53. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792 [TBL] [Abstract][Full Text] [Related]
54. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Lelièvre L; Clézardin P; Magaud L; Roche L; Tubiana-Mathieu N; Tigaud JD; Topart D; Raban N; Mouret-Reynier MA; Mathevet P Clin Breast Cancer; 2018 Dec; 18(6):e1311-e1321. PubMed ID: 30098917 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Chen T; Berenson J; Vescio R; Swift R; Gilchick A; Goodin S; LoRusso P; Ma P; Ravera C; Deckert F; Schran H; Seaman J; Skerjanec A J Clin Pharmacol; 2002 Nov; 42(11):1228-36. PubMed ID: 12412821 [TBL] [Abstract][Full Text] [Related]
56. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. Huang WW; Huang C; Liu J; Zheng HY; Lin L PLoS One; 2012; 7(7):e40783. PubMed ID: 22844410 [TBL] [Abstract][Full Text] [Related]
57. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. Tang JH; Zhao JH; Lu JW; Yan F; Qin JW; Xu B J Cancer Res Clin Oncol; 2011 Jan; 137(1):55-63. PubMed ID: 20221635 [TBL] [Abstract][Full Text] [Related]
58. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Song Z; Zhang Y Med Oncol; 2014 Apr; 31(4):898. PubMed ID: 24573639 [TBL] [Abstract][Full Text] [Related]
59. Electrolyte abnormalities with zoledronic acid therapy. Sorscher SM Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414 [No Abstract] [Full Text] [Related]
60. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis. Yazici O; Aksoy S; Ucar O; Ozdemir N; Demir M; Sendur MA; Arik Z; Yaman S; Eren T; Uncu D; Zengin N Med Oncol; 2013; 30(3):609. PubMed ID: 23690271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]